We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+50.74%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.11B
AUM Growth
+$318M
Cap. Flow
+$94.6M
Cap. Flow %
8.53%
Top 10 Hldgs %
61.72%
Holding
56
New
18
Increased
10
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$46.5M
2
ARVN icon
Arvinas
ARVN
+$39.2M
3
ASMB icon
Assembly Biosciences
ASMB
+$35.2M
4
IPHA
Innate Pharma
IPHA
+$27.9M
5
MRUS
Merus
MRUS
+$25M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$69.3M
2
ARGX icon
argenx
ARGX
+$44.5M
3
SLDB icon
Solid Biosciences
SLDB
+$34.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$8.42M

Sector Composition

Rank Sector Weight
1 Healthcare 95%
2 Miscellaneous 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$149M 13.45%
9,426,640
– –
XNCR icon
2
Xencor
XNCR
$1.94B
$86M 7.75%
2,501,557
– –
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$79.9M 7.2%
3,627,597
-335,381
-8% -$6.75M
KYNB
4
Kyntra Bio
KYNB
$32.5M
$64M 5.77%
59,689
+7,937
+15% +$8.1M
KURA icon
5
Kura Oncology
KURA
$1.13B
$58.3M 5.26%
4,241,953
+200,000
+5% +$2.96M
IRWD icon
6
Ironwood Pharmaceuticals
IRWD
$682M
$58.2M 5.24%
4,371,408
-300,000
-6% -$3.31M
ARVN icon
7
Arvinas
ARVN
$600M
$55M 4.96%
+1,339,069
New +$39.2M
ASMB icon
8
Assembly Biosciences
ASMB
$694M
$48.9M 4.4%
199,022
+190,972
+2,372% +$35.2M
NGNE icon
9
Neurogene
NGNE
$732M
$48.2M 4.35%
195,794
+82,500
+73% +$8.22M
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$37M 3.33%
2,154,845
-6,675
-0.3% -$104K
PRVL
11
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$35.6M 3.21%
2,248,306
-144,250
-6% -$1.84M
ARGX icon
12
argenx
ARGX
$64B
$32.4M 2.92%
202,117
-329,048
-62% -$44.5M
ANAB icon
13
AnaptysBio
ANAB
$1.67B
$31.9M 2.88%
+1,966,100
New +$46.5M
IPHA
14
Innate Pharma
IPHA
$248M
$29.3M 2.64%
+4,545,454
New +$27.9M
KYNB
15
CALL
Kyntra Bio
KYNB
$32.5M
$29M 2.62%
27,060
+960
+4% +$980K
BMRN icon
16
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
$26.4M 2.38%
+312,500
New +$23.6M
MRUS
17
DELISTED
Merus
MRUS
$24.2M 2.18%
1,718,200
+1,552,600
+938% +$25M
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$22.9M 2.07%
1,481,411
– –
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$5.02B
$21.4M 1.93%
+500,000
New +$21.8M
CHMA
20
DELISTED
Chiasma, Inc. Common Stock
CHMA
$15.1M 1.36%
3,043,827
– –
HARP
21
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13.4M 1.21%
90,855
-55,487
-38% -$8.42M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$12.5M 1.13%
+173,364
New +$21.3M
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.52B
$11.2M 1.01%
261,554
+200,000
+325% +$8.25M
RNAC icon
24
Cartesian Therapeutics
RNAC
$290M
$10.9M 0.99%
+153,257
New +$7.39M
XCUR icon
25
Exicure
XCUR
$8.44M
$10.1M 0.91%
23,628
-13,140
-36% -$5.38M
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2019 Portfolio in Review

As of Q4 2019, EcoR1 Capital held 56 positions worth $1.11B, up 40% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

EcoR1 Capital deployed $94.6M of net new capital in Q4 2019, opening 18 new positions and adding to 10 existing holdings. Its largest new stake was AnaptysBio: 1,966,100 shares worth $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was argenx, an estimated $44.5M trimmed.

  • EcoR1 Capital's largest Q4 2019 buy was AnaptysBio: 1,966,100 shares worth $31.9M.
  • EcoR1 Capital added most to Assembly Biosciences in Q4 2019, an estimated $35.2M increase.
  • EcoR1 Capital's biggest Q4 2019 reduction was argenx, cutting an estimated $44.5M.
  • EcoR1 Capital fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $69.3M.
  • EcoR1 Capital's ten largest holdings make up 62% of its $1.11B portfolio in Q4 2019.
  • EcoR1 Capital opened 18 new positions and closed 12 in Q4 2019.
  • EcoR1 Capital's portfolio value rose 40% quarter-over-quarter to $1.11B.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.